Bumetanide: Clinical Overview
Indications
Bumetanide is indicated for treating edema associated with congestive heart failure, hepatic disease, renal disease (including nephrotic syndrome), and acute pulmonary congestion 1. Loop diuretics like bumetanide are the preferred diuretic class for most heart failure patients with evidence of congestion or fluid retention 2.
Key clinical contexts:
- Heart failure with fluid overload: First-line loop diuretic option alongside furosemide and torsemide
- Renal disease with edema: Effective even in chronic renal insufficiency, though higher doses may be required
- Hepatic cirrhosis with ascites: Alternative when oral absorption is compromised
- Furosemide allergy: Successful use following allergic reactions to furosemide suggests lack of cross-sensitivity 1
Dosing
Oral Administration
Initial dose: 0.5-1.0 mg once or twice daily 2
- Maximum daily dose: 10 mg 2
- Duration of action: 4-6 hours 2
- Start low and titrate upward until achieving 0.5-1.0 kg daily weight loss 2
Parenteral Administration (IV/IM)
Initial dose: 0.5-1.0 mg IV or IM 1
- IV administration: Give over 1-2 minutes 1
- If insufficient response, repeat doses at 2-3 hour intervals
- Maximum daily dose: 10 mg 1
- Use parenteral route when GI absorption is impaired or oral administration impractical 1
- Transition to oral therapy as soon as feasible 1
Continuous Infusion
For refractory cases, particularly in chronic renal insufficiency:
- Continuous infusion is more efficacious than bolus therapy in severe CRI 3
- Typical infusion rate: ~0.046 mg/kg/hr (range 0.005-0.3 mg/kg/hr in pediatric cardiac populations) 4
- Mean treatment duration: 45 hours 5
- Produces greater net sodium excretion with less toxicity compared to bolus dosing 3
Special Populations
- Chronic renal failure/nephrotic syndrome: May require up to 15 mg/day 6
- Refractory edema: Consider combination with thiazide diuretics (metolazone or chlorothiazide) for sequential nephron blockade 2
Potency Comparison
Bumetanide is approximately 40-fold more potent than furosemide (1 mg bumetanide ≈ 40-60 mg furosemide) 6, 7, with superior oral bioavailability 2.
Contraindications
Absolute contraindications 1:
- Anuria
- Hepatic coma
- Severe electrolyte depletion (until corrected)
- Hypersensitivity to bumetanide
Relative contraindications/discontinuation criteria 1:
- Marked increase in BUN or creatinine during therapy
- Development of oliguria in progressive renal disease
- Uncorrected severe hypovolemia
Monitoring Recommendations
Electrolyte Monitoring
- Potassium: Risk of hypokalemia, though less than with furosemide for equivalent diuresis 6
- Sodium: Monitor for hyponatremia, particularly in heart failure patients 2
- Consider potassium supplementation or spironolactone co-administration in at-risk patients 6
Renal Function
- Monitor BUN and creatinine: Particularly important as increasing doses correlate with increased AKI incidence (24.7% with continuous infusion) 5
- Urine output: Target response of ~1.88 mL/kg/hr with continuous infusion 5
- Glomerular filtration rates typically remain unaffected in most patients 6
Clinical Parameters
- Daily weights: Target 0.5-1.0 kg daily loss during active diuresis 2
- Volume status: Assess for resolution of edema, jugular venous distension, pulmonary congestion
- Blood pressure: Monitor for hypotension with aggressive diuresis
Safety Monitoring
- Ototoxicity: Audiological impairment occurs less frequently than with furosemide 6
- Muscle cramps: Not uncommon in chronic renal failure patients 6
- Hyperuricemia: Common with all loop diuretics 7
Important Clinical Considerations
Diuretic Resistance
When patients become unresponsive to high-dose therapy 2:
- Assess dietary sodium intake (restrict to <2-3 g/day)
- Discontinue NSAIDs and other diuretic-blocking agents
- Evaluate renal perfusion
- Consider IV administration (bolus or continuous infusion) 2
- Add thiazide diuretic for combination therapy 2
Combination Therapy
Never use diuretics in isolation for heart failure—always combine with guideline-directed medical therapy (GDMT) that reduces hospitalizations and mortality, as diuretics alone have uncertain effects on morbidity and mortality 2.
Solution Compatibility
When preparing IV solutions, use within 24 hours of preparation. Compatible with 5% dextrose, 0.9% sodium chloride, and lactated Ringer's solution 1.